دورية أكاديمية
أعرض في EDS

Formulation and in vitro evaluation of salbutamol sulphate in situ gelling nasal inserts.

التفاصيل البيبلوغرافية
العنوان: Formulation and in vitro evaluation of salbutamol sulphate in situ gelling nasal inserts.
المؤلفون: Farid RM; Department of Pharmaceutics, Faculty of Pharmacy and Drug Manufacturing, Pharos University, Alexandria, Egypt. ragwaf@yahoo.com, Etman MA, Nada AH, Ebian Ael A
المصدر: AAPS PharmSciTech [AAPS PharmSciTech] 2013 Jun; Vol. 14 (2), pp. 712-8. Date of Electronic Publication: 2013 Mar 21.
نوع المنشور: Evaluation Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 100960111 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1530-9932 (Electronic) Linking ISSN: 15309932 NLM ISO Abbreviation: AAPS PharmSciTech Subsets: MEDLINE
أسماء مطبوعة: Publication: New York : Springer
Original Publication: Arlington, VA : American Association of Pharmaceutical Scientists, c2000-
مواضيع طبية MeSH: Drug Carriers*, Albuterol/*chemistry , Bronchodilator Agents/*chemistry , Polymers/*chemistry, Adhesiveness ; Administration, Intranasal ; Albuterol/administration & dosage ; Alginates/chemistry ; Bronchodilator Agents/administration & dosage ; Calorimetry, Differential Scanning ; Carboxymethylcellulose Sodium/chemistry ; Chemistry, Pharmaceutical ; Chitosan/chemistry ; Delayed-Action Preparations ; Diffusion ; Gels ; Glucuronic Acid/chemistry ; Hexuronic Acids/chemistry ; Hydrogen-Ion Concentration ; Hydrophobic and Hydrophilic Interactions ; Hypromellose Derivatives ; Kinetics ; Methylcellulose/analogs & derivatives ; Methylcellulose/chemistry ; Mucins/chemistry ; Solubility ; Surface Properties ; Technology, Pharmaceutical/methods
مستخلص: The aim of this study was to formulate salbutamol sulfate (SS), a model drug, as mucoadhesive in situ gelling inserts having a high potential as nasal drug delivery system bypassing the first-pass metabolism. In situ gelling inserts, each containing 1.4% SS and 2% gel-forming polymer, hydroxypropyl methylcellulose (HPMC), carboxymethylcellulose sodium (CMC Na), sodium alginate (AL), and chitosan (CH) were prepared. The inserts were investigated for their different physicochemical properties. The weight of inserts was 16-27 mg, drug content was 3.9-4.2 mg, thickness ranged between 15 and 28 μm and surface pH was 5-7. Cumulative drug released from the inserts exhibited extended release for more than 10 h following the decreasing order: CH>AL>CMC Na>HPMC. The drug release from CMC Na and AL inserts followed zero-order kinetics while HPMC and CH inserts exhibited non-Fickian diffusion mechanism. The inserts exhibited different water uptake (7-23%) with the smallest values for CH. Differential scanning calorimetry study pointed out possible interaction of SS and oppositely charged anionic polymers (CMC Na and AL). The mucoadhesive in situ gelling inserts exhibited satisfactory mucoadhesive and extended drug release characteristics. The inserts could be used for nasal delivery of SS over about 12 h; bypassing the hepatic first-pass metabolism without potential irritation.
References: J Control Release. 2014 Sep 28;190:31-2. (PMID: 25356469)
J Pharm Pharmacol. 2003 Dec;55(12):1623-7. (PMID: 14738587)
Drug Deliv. 2006 Jan-Feb;13(1):31-8. (PMID: 16401591)
Acta Pharm. 2003 Sep;53(3):199-212. (PMID: 14769243)
Eur J Pharm Biopharm. 2006 Jul;63(3):310-9. (PMID: 16513333)
Br J Clin Pharmacol. 1986 Nov;22(5):587-93. (PMID: 3790406)
Crit Rev Ther Drug Carrier Syst. 1988;5(1):21-67. (PMID: 3293807)
J Control Release. 2004 Aug 11;98(2):269-79. (PMID: 15262418)
Eur J Pharm Sci. 2006 Jan;27(1):62-71. (PMID: 16213127)
Int J Pharm. 2005 Mar 3;291(1-2):69-77. (PMID: 15707733)
Eur J Pharm Sci. 2007 May;31(1):25-31. (PMID: 17368006)
AAPS PharmSciTech. 2006 Mar 10;7(1):E19. (PMID: 16584149)
J Drug Target. 2010 Apr;18(3):235-42. (PMID: 19929307)
Pharm Res. 2002 Jul;19(7):998-1008. (PMID: 12180553)
Pharm Res. 1995 Nov;12(11):1781-5. (PMID: 8592686)
Int J Pharm. 2000 Apr 5;198(2):139-46. (PMID: 10767563)
J Pharm Pharmacol. 1975 Jan;27(1):48-9. (PMID: 235616)
AAPS PharmSciTech. 2005 Sep 30;6(2):E184-9. (PMID: 16353976)
Vaccine. 2011 Nov 8;29(48):9026-37. (PMID: 21939718)
J Pharm Pharmacol. 2001 Aug;53(8):1047-67. (PMID: 11518015)
Int J Pharm. 2010 Nov 15;400(1-2):59-65. (PMID: 20801202)
J Pharm Sci. 2000 Jul;89(7):850-66. (PMID: 10861586)
AAPS PharmSciTech. 2007 Oct 12;8(4):E81. (PMID: 18181542)
J Pharm Sci. 1985 Mar;74(3):283-9. (PMID: 2989483)
Indian J Pharm Sci. 2008 Sep;70(5):631-5. (PMID: 21394260)
J Control Release. 1998 Jan 2;50(1-3):167-78. (PMID: 9685883)
J Pharm Sci. 1983 Oct;72(10):1189-91. (PMID: 6644570)
Colloids Surf B Biointerfaces. 2011 Jun 1;84(2):384-9. (PMID: 21320767)
Int J Pharm. 2005 Nov 4;304(1-2):72-82. (PMID: 16183221)
J Drug Target. 2010 May;18(4):321-31. (PMID: 20199172)
Drug Dev Ind Pharm. 2010 May;36(5):581-93. (PMID: 19954407)
Drug Dev Ind Pharm. 2003 May;29(5):595-602. (PMID: 12779289)
Int J Pharm. 2003 Oct 2;264(1-2):1-14. (PMID: 12972331)
J Microencapsul. 2012;29(2):103-14. (PMID: 22047546)
J Control Release. 2004 Sep 14;99(1):73-82. (PMID: 15342182)
المشرفين على المادة: 0 (Alginates)
0 (Bronchodilator Agents)
0 (Delayed-Action Preparations)
0 (Drug Carriers)
0 (Gels)
0 (Hexuronic Acids)
0 (Mucins)
0 (Polymers)
3NXW29V3WO (Hypromellose Derivatives)
8A5D83Q4RW (Glucuronic Acid)
9004-67-5 (Methylcellulose)
9012-76-4 (Chitosan)
K679OBS311 (Carboxymethylcellulose Sodium)
QF8SVZ843E (Albuterol)
تواريخ الأحداث: Date Created: 20130322 Date Completed: 20131017 Latest Revision: 20231106
رمز التحديث: 20240513
مُعرف محوري في PubMed: PMC3666017
DOI: 10.1208/s12249-013-9956-y
PMID: 23516112
قاعدة البيانات: MEDLINE
الوصف
تدمد:1530-9932
DOI:10.1208/s12249-013-9956-y